Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
阿贝西利联合内分泌治疗激素受体阳性、HER2阴性、淋巴结阳性、高危早期乳腺癌（monarchE）：一项随机、开放标签、3期试验的预先计划中期分析结果
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(22)00694-5
Johnston, Stephen R D; Toi, Masakazu; O'Shaughnessy, Joyce; Rastogi, Priya; Campone, Mario; Neven, Patrick; Huang, Chiun-Sheng; Huober, Jens; Jaliffe, Georgina Garnica; Cicin, Irfan; Tolaney, Sara M; Goetz, Matthew P; Rugo, Hope S; Senkus, Elzbieta; Testa, Laura; Del Mastro, Lucia; Shimizu, Chikako; Wei, Ran; Shahir, Ashwin; Munoz, Maria; San Antonio, Belen; André, Valérie; Harbeck, Nadia; Martin, Miguel
